BAM vs JPM

The Advanced Deterministic Scorecard reveals a weak Piotroski F-Score of 3/9, indicating poor financial health, which raises concerns despite strong profitability and growth metrics. The absence of an Altman Z-Score prevents a full distress risk assessment, but the low Piotroski score suggests operational or balance sheet weaknesses. While the company exhibits robust ROE (22.57%), high margins, and strong earnings growth (34.3% YoY), these are offset by an elevated valuation (P/E 33.29, P/B 9.77) and a concerning 109.19% payout ratio that threatens dividend sustainability. Price performance has weakened recently, with a 1Y return of -9.3%, and insider sentiment is neutral, offering no catalysts.

JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.